<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00962182</url>
  </required_header>
  <id_info>
    <org_study_id>HP-03</org_study_id>
    <nct_id>NCT00962182</nct_id>
  </id_info>
  <brief_title>Study of Enzyme Supplements to Treat Celiac Disease</brief_title>
  <official_title>Effect of a Cocktail of Two Common Enzyme Supplements on Celiac Disease Patients With Persistent Seropositivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heim Pal Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heim Pal Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether a cocktail of two common food-grade enzyme
      supplements leads to decrease of serum activity markers in celiac disease patients
      insufficiently treated by previous gluten exclusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Celiac disease is genetically determined abnormal immune response to gluten, a component of
      wheat, rye and barley proteins that cause damage to the villous structure in the small bowel.
      The active disease is characterized by the induction of gluten-dependent autoantibodies to
      transglutaminase type-2, which are sensitive and specific non-invasive markers of
      gluten-sensitivity. Gluten-free diet normally leads to clearance of antibodies from serum in
      6-12 months. Persistent seropositivity is a problem in patients who only incompletely exclude
      gluten or frequently transgress the diet. In such cases, damage of the small bowel may
      persist and complications may occur at higher frequency. The central hypothesis to be tested
      is that enzyme treatment designed to degrade a certain amount of gluten before absorption in
      the gastrointestinal tract will lead to a clinically meaningful decrease in auto-antibody
      levels in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative seroconversion or a drop of more than 50% in anti-transglutaminase antibody blood levels by ELISA</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negative seroconversion or drop of at least two dilution steps in the EMA test</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative conversion for celiac antibodies in the blood by the rapid test</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptoms or rash (if any)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Favorable changes in morphometry in small bowel biopsy specimens</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Celiac Disease</condition>
  <condition>Dermatitis Herpetiformis</condition>
  <arm_group>
    <arm_group_label>Enzyme treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enzyme for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo enzyme for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enzyme + gluten</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enzyme and 500 mg gluten b.i.d. for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STAN1</intervention_name>
    <description>3-4 capsules/day at meals</description>
    <arm_group_label>Enzyme treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo enzyme</intervention_name>
    <description>3-4 capsules/day at meals</description>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STAN1+gluten</intervention_name>
    <description>3-4 capsules/day at meals plus 500 mg gluten b.i.d</description>
    <arm_group_label>Enzyme + gluten</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Celiac disease diagnosed by small intestinal biopsy

          -  More than 12 months elapsed since initial diagnosis and start of the dietary treatment

          -  Evidence for ongoing active disease as verified by seropositivity or dermatitis
             herpetiformis rash

          -  Subject agrees to follow a gluten-free diet

        Exclusion Criteria:

          -  Other gastrointestinal or hepatic disease besides celiac disease

          -  Selective IgA deficiency

          -  Use of dapsone or diaphenylsulfone

          -  Pregnancy and breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilma Korponay-Szabo, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Heim Pal Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heim Pal Children's Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2009</study_first_submitted>
  <study_first_submitted_qc>August 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2009</study_first_posted>
  <last_update_submitted>March 4, 2018</last_update_submitted>
  <last_update_submitted_qc>March 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heim Pal Children's Hospital</investigator_affiliation>
    <investigator_full_name>Ilma R Korponay-Szabo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>celiac disease</keyword>
  <keyword>transglutaminase antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Celiac Disease</mesh_term>
    <mesh_term>Dermatitis Herpetiformis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

